Phase II/III trial of cemiplimab PD-1 inhibitor in advanced NSCLC.

This randomized study compares adding cemiplimab to docetaxel and ramucirumab versus standard therapy in patients with stage IV or recurrent non-small cell lung cancer after platinum-based chemotherapy and immunotherapy. Sponsored by SWOG Cancer Research Network, the trial incorporates imaging and biospecimen analyses to evaluate treatment efficacy.